Key result
LivIQ DX leadless pacemaker maintains 100% resting AV synchrony and stable electrical performance in sheep.
Why the study?
Current leadless ventricular pacemakers either provide asynchronous pacing only or achieve AV synchrony with variable consistency.
Does the LivIQ DX leadless pacemaker provide safe and effective AV-synchronous pacing in a sheep model?
Does the LivIQ DX leadless pacemaker provide safe and effective AV-synchronous pacing in a sheep model?
A novel AV-synchronous leadless pacemaker with far-field atrial sensing demonstrated safety and reliable electrical performance in a chronic 12-week sheep model.
New AVS leadless pacemaker evaluation in Level 5 data leaves open questions on safety, efficacy, and adoption; larger trials needed.
BACKGROUND: Ventricular leadless pacemakers offer a valuable alternative to conventional transvenous systems by markedly reducing complications related to leads and device pockets. However, current leadless ventricular devices either provide asynchronous pacing only or achieve AV synchrony (AVS) with variable consistency, largely influenced by the underlying sinus rate, the pacing indication, and the programmed pacing strategy. OBJECTIVE: To evaluate safety and efficacy of a new AVS leadless pacemaker system in a GLP animal study. METHODS: The LivIQ DX pacemaker, a sub 1-cc VDD implant with tine fixation and electrical far-field sensing of the p-wave, was implanted in nine sheep via jugular access in a GLP study. Safety was evaluated during the implant procedure, and via regular blood panels, ambulatory pacemaker data collection, and necropsy examination at 12 weeks post-implantation. Efficacy was assessed using R-wave amplitude, pacing capture threshold, and pacing impedance. AVS was evaluated at rest and during a stress test. RESULTS: The LivIQ was successfully implanted in all sheep with no serious adverse events. Electrical values were stable throughout the 12-week duration, with a mean p-wave amplitude of 71±39 μV, R-wave amplitude of 9.9±4.1 mV, pacing capture threshold of 0.8±0.4 V at 0.25 ms, and pacing impedance of 869±233 Ohms. All subjects were 100% AV-synchronous at rest during AsVp tracking and AVS was maintained up to 140 bpm during the stress test. There were no clinically significant observations at necropsy. CONCLUSION: This study highlights the safe implantation and reliable electrical performance of a novel leadless pacemaker, demonstrating high AVS in a chronic sheep model.
No takes yet. Share an insight, caveat, or question.
Garweg et al. (2026) studied this question. LivIQ DX pacemaker was evaluated on Safety and efficacy (electrical values and AV synchrony). The LivIQ DX leadless pacemaker was safely implanted in 9 sheep, demonstrating stable electrical performance and 100% AV synchrony at rest over 12 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: